Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines

BMC Immunology

Volumn 15, Issue 1, 2014, Pages

  Lin, Hugo You Hsien ^a,b,d   Chang, Kai Ting ^a,c,d   Hung, Chi Chih ^a   Kuo, Chang Hung ^a,b   Hwang, Shang Jyh ^a,b   Chen, Hung Chun ^a,b   Hung, Chih Hsing ^a,c,d   Lin, Sheng Fung ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemokine; Glomerulonephritis; mTOR

Indexed keywords

CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RAPAMYCIN; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; FLAVONOID; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MONOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; SECRETION (PROCESS);

ANTHRACENES; CELL LINE; CELL SURVIVAL; CHEMOKINES; FLAVONOIDS; HUMANS; LIPOPOLYSACCHARIDES; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84949117579     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/s12865-014-0037-0     Document Type: Article

References (46)

1. Liu Y: Rapamycin and chronic kidney disease: beyond the inhibition of inflammation. Kidney Int 2006, 69(11):1925-1927.
2. Brunskill NJ: Rapamycin: a new string to the antiproteinuric bow? J Am Soc Nephrol 2005, 16(7):1878-1879.
3. Guertin DA, Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 2005, 11(8):353-361.
4. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wülfert E: Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005, 111(8):1040-1044.
5. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):140-151.
6. Gouras GK: mTOR: at the crossroads of aging, chaperones, and Alzheimer's disease. J Neurochem 2013, 124(6):747-748.
7. Kirsch AH, Riegelbauer V, Tagwerker A, Rudnicki M, Rosenkranz AR, Eller K: The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am J Physiol Renal Physiol 2012, 303(4):F569-F575.
8. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8(2):128-135.
9. Liern M, De Reyes V, Fayad A, Vallejo G: Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome. Nefrologia 2012, 32(3):321-328.
10. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005, 16(7):2063-2072.
11. Mackay CR: Chemokines: immunology's high impact factors. Nat Immunol 2001, 2(2):95-101.
12. Vielhauer V, Kulkarni O, Reichel CA, Anders HJ: Targeting the recruitment of monocytes and macrophages in renal disease. Semin Nephrol 2010, 30(3):318-333.
13. Singh RG, Usha, Rathore SS, Behura SK, Singh NK: Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus 2012, 21(11):1214-1218.
14. Souto MF, Teixeira AL, Russo RC, Penido MG, Silveira KD, Teixeira MM, Simoes ESAC: Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria. Pediatr Res 2008, 64(6):637-642.
15. Zwiech R: Predictive value of conjointly examined IL-1ra, TNF-R I, TNF-R II, and RANTES in patients with primary glomerulonephritis. J Korean Med Sci 2013, 28(2):261-267.
16. Cockwell P, Howie AJ, Adu D, Savage CO: In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int 1998, 54(3):827-836.
17. Gu L, Tseng SC, Rollins BJ: Monocyte chemoattractant protein-1. Chem Immunol 1999, 72:7-29.
18. Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G: CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014, 74(2):436-445.
19. Lin J, Kakkar V, Lu X: Impact of MCP-1 in Atherosclerosis. Curr Pharm Des 2014, 20(28):4580-4588.
20. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H: Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007, 360(4):772-777.
21. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Kolodziejczyk Z: Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol 2011, 45(1):52-59.
22. Dworacka M, Krzyzagorska E, Wesolowska A, Zharmakhanova G, Iskakova S, Dworacki G: Circulating monocyte chemotactic protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1) and angiogenin in type 2 diabetic patients treated with statins in low doses. Eur J Pharmacol 2014, 740:474-9.
23. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM: A human T cell-specific molecule is a member of a new gene family. J Immunol 1988, 141(3):1018-1025.
24. Aldinucci D, Colombatti A: The inflammatory chemokine CCL5 and cancer progression. Mediat Inflamm 2014, 2014:292376.
25. Tripathy D, Thirumangalakudi L, Grammas P: RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging 2010, 31(1):8-16.
26. Mezzano SA, Droguett MA, Burgos ME, Ardiles LG, Aros CA, Caorsi I, Egido J: Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int 2000, 57(1):147-158.
27. Krensky AM, Ahn YT: Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007, 3(3):164-170.
28. Cho MH, Lee HS, Choe BH, Kwon SH, Chung KY, Koo JH, Ko CW: Interleukin-8 and tumor necrosis factor-alpha are increased in minimal change disease but do not alter albumin permeability. Am J Nephrol 2003, 23(4):260-266.
29. Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K: Interleukin-8 and interleukin-17 for cancer. Cancer Investig 2014, 32(5):197-205.
30. Signorelli SS, Fiore V, Malaponte G: Inflammation and peripheral arterial disease: the value of circulating biomarkers (Review). Int J Mol Cell Med 2014, 33(4):777-783.
31. Yuan Y, Li P, Ye J: Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. Protein Cell 2012, 3(3):173-181.
32. Vistnes M: Macrophage inflammatory protein-1beta: a novel prognostic biomarker in atherosclerosis? Cardiology 2012, 121(3):149-151.
33. Wada T, Furuichi K, Segawa-Takaeda C, Shimizu M, Sakai N, Takeda SI, Takasawa K, Kida H, Kobayashi KI, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H: MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999, 56(3):995-1003.
34. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005, 17(6):596-603.
35. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351(26):2715-2729.
36. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E: Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004, 17(4):215-220.
37. Izzedine H, Brocheriou I, Frances C: Post-transplantation proteinuria and sirolimus. N Engl J Med 2005, 353(19):2088-2089.
38. Singer SJ, Tiernan R, Sullivan EJ: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000, 343(24):1815-1816.
39. Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-Bruneel MF, Varet B, Kreis H, Morelon E: Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005, 80(9):1212-1219.
40. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Horl WH, Hengstschlager M, Müller M, Säemann MD: The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29(4):565-577.
41. Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, Melzi R, Maffi P, Secchi A, Sordi V, Piemonti L: Rapamycin unbalances the polarization of human macrophages to M1. Immunology 2013, 140(2):179-190.
42. Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ: Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway. Am J Pathol 2004, 164(2):477-485.
43. Schieppati A, Remuzzi G: Proteinuria and its consequences in renal disease. Acta Paediatr Suppl 2003, 92(443):9-13. discussion 15.
44. Bagga A, Mantan M: Nephrotic syndrome in children. Indian J Med Res 2005, 122(1):13-28.
45. Yang CW, Ahn HJ, Jung JY, Kim WY, Li C, Choi BS, Kim HW, Kim YS, Moon IS, Kim J, Bang BK: Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. Transplantation 2003, 75(1):20-24.
46. Andreucci M, Faga T, Lucisano G, Uccello F, Pisani A, Memoli B, Sabbatini M, Fuiano G, Michael A: Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chem Biol Interact 2010, 185(3):253-262.